You just read:

Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer

News provided by

Merrimack Pharmaceuticals, Inc.

Feb 26, 2018, 06:55 ET